CEVEC Pharmaceuticals GmbH (CEVEC) signed an option and license agreement with Roche for the use of its newly launched ELEVECTA Technology for large scale manufacturing of adeno-associated virus (AAV) vectors for gene therapy applications. Under the agreement, Roche and Spark Therapeutics, a member of the Roche Group, have an option for a non-exclusive license for the development of AAV producer cell lines based on CEVEC’s ELEVECTA Technology. The partnership will provide Roche the righ...